← board
DRMA
Dermata Therapeuticsdistress 7/10 · high distress / dilution risk$1.23-2%today-83% from 52w high
Dermatology 1
Lead: acne
Revenue
pre-revenue
Liquidity
$7M
Runway
0.8 yrs
Shares 1y
+490%
Price & events
-49.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.4%
1D
-3.9%
1W
+0.0%
1M
-2.8%
3M
-43.3%
6M
-82.8%
1Y
-90.5%
2Y
—
5Y
-100.0%
All
Overview
- Market Cap
- $4.95M
- Volume
- 1.36K
- 52 Week Range
- $1.14 – $7.30
- Total Shares
- 4.02M
- Float Shares
- 3.17M
- Short %
- 4.17%
- % Held by Insiders
- 24.82%
- % Held by Institutions
- 7.37%
- RVOL
- 0.02x
- Beta
- 0.67
Pipeline stages · 1 programs
DMT310, Placebo
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-03-31 | Phase 3 | DMT310, Placebo | Acne Vulgaris | 520 | completed |
Catalyst news & presentations · 2
- September 17, 2025conferencedata presentationsecondaryPhase 3XYNGARI (DMT310) · Presented Phase 3 STAR-1 data at EADV Congress 2025SEC 8-K
- 2025-09-10withdrawalXYNGARI · Withdrew investigational new drug application for XYNGARISEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 4,022,143 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-08-21Maxim GroupBuy
- 2025-05-21Maxim GroupBuy
- 2024-08-21Maxim GroupBuy
Competitors — acne
Recent news
- 2026-07-19Price to earnings forward of Dermata Therapeutics, Inc. – NASDAQ:DRMAW - TradingView
- 2026-07-14Price-Driven Insight from (DRMA) for Rule-Based Strategy - Stock Traders Daily
- 2026-07-14Price-Driven Insight from (DRMA) for Rule-Based Strategy - Stock Traders Daily
- 2026-07-06DRMA Q1 2026 Earnings: EPS Surprise of 11.21% Beats Estimates Amid No Revenue Generation - Dividend Earnings Report - dars.gov.et
- 2026-07-02Dermata Therapeutics Warrant (DRMAW) Holds at $0.01 – Warrants Remain at Key Support Level - Technical Analysis Picks - dars.gov.et
- 2026-06-25DRMA Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-18Dermata Therapeutics Inc (DRMA) Institutional Confidence - TradingKey
- 2026-06-15Dermata Therapeutics Poised for Expansion with Strategic Skincare Launch - timothysykes.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.